688212.SHG Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A
- Market cap
- CNY 3.57B
- P/E
- -
- P/B
- 2.99x
- ROE
- -10.8%
- Dividend yield
- 0.46%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 688212.SHG undervalued?
Graham numberThe Graham number of Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A fundamental analysis
No fundamental analysis for Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A yet.
Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A
Shanghai Aohua Photoelectricity Endoscope Co., Ltd. engages in the research and development, manufacture, and sale of electronic endoscope equipment and endoscopic diagnosis and treatment consumables in China and internationally. It offers electronic digestive endoscopes, otolaryngoscopes, and endoscopic diagnostic and treatment consumables for use in respiratory medicine, general surgery, otolaryngology, orthopedics, urology, gynecology, gastroenterology, and emergency medi…
Full company profileShanghai Aohua Photoelectricity Endoscope Co. Ltd. A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 298M | 263M | 347M | 445M | 678M | 750M | 774M | 606M |
| Gross Profit | 204M | 177M | 240M | 310M | 473M | 511M | 505M | 395M |
| Operating Income | 65.0M | 27.7M | 65.6M | 2.32M | 66.8M | 34.3M | 42.0M | -114M |
| EBITDA | 66.8M | 45.2M | 84.2M | 52.9M | 103M | 72.0M | 80.2M | -152M |
| Net Income | 52.9M | 18.5M | 57.0M | 21.7M | 57.9M | 21.0M | 11.5M | -130M |
| EPS | 0.53 | 0.19 | 0.43 | 0.16 | 0.43 | 0.16 | 0.09 | -0.97 |
| Balance Sheet | ||||||||
| Total Assets | 600M | 632M | 1.35B | 1.46B | 1.60B | 1.75B | 2.00B | 1.98B |
| Total Liabilities | 78.4M | 86.8M | 90.4M | 178M | 200M | 368M | 670M | 761M |
| Shareholders' Equity | 512M | 534M | 1.25B | 1.27B | 1.38B | 1.37B | 1.31B | 1.21B |
| Cash & Short-term Investments | 162M | 177M | 767M | 230M | 245M | 267M | 342M | 290M |
| Cash Flow | ||||||||
| Operating Cash Flow | 47.4M | 71.5M | 66.2M | -41.9M | 37.4M | -78.9M | -20.4M | - |
| Capital Expenditure | 65.5M | 61.8M | 91.6M | 78.8M | 158M | 187M | 130M | 68.7M |
| Free Cash Flow | -18.1M | 9.69M | -25.5M | -121M | -120M | -266M | -151M | -277M |
| Ratios | ||||||||
| ROE | 10.3% | 3.5% | 4.6% | 1.7% | 4.2% | 1.5% | 0.9% | -10.8% |
| ROA | 8.8% | 2.9% | 4.2% | 1.5% | 3.6% | 1.2% | 0.6% | -6.6% |
| Net Profit Margin | 17.8% | 7.0% | 16.4% | 4.9% | 8.5% | 2.8% | 1.5% | -21.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A dividends
- Dividend yield
- 0.46%
- Forward dividend
- -
- Payout ratio
- 144.7%
- Ex-dividend date
- Jun 18, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 16.6M | 0.12 | 144.7% |
| 2024 | CNY 41.6M | 0.31 | 198.0% |
| 2023 | CNY 1.63M | 0.01 | 2.8% |
| 2022 | CNY 25.3M | 0.19 | 116.9% |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | CNY 64.5K | 0.00 | 0.1% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A
- Insiders 32.86%
- Institutions 20.16%
- Public & others 46.99%
- Shares outstanding 135M
- Free float 87.6M
Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A company profile
- Company name
- Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A
- Ticker
- 688212.SHG
- ISIN
- CNE100004ZJ5
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 1,159
- Fiscal year end
- December
- Address
- No.66, Lane 133, Guangzhong Road, Shanghai, China, 201108
- Phone
- 86 21 5430 3731
- Website
- aohua.com
About Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A
Shanghai Aohua Photoelectricity Endoscope Co., Ltd. engages in the research and development, manufacture, and sale of electronic endoscope equipment and endoscopic diagnosis and treatment consumables in China and internationally. It offers electronic digestive endoscopes, otolaryngoscopes, and endoscopic diagnostic and treatment consumables for use in respiratory medicine, general surgery, otolaryngology, orthopedics, urology, gynecology, gastroenterology, and emergency medicine. Shanghai Aohua Photoelectricity Endoscope Co., Ltd. was founded in 1994 and is based in Shanghai, China.
Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A management
6- Mr. Xiaozhou GuGM & Chairman · born 1984
- Mr. Cheng Hao QianCFO, Deputy GM & Director · born 1981
- Mr. Xiaojiang ShiDeputy GM & Secretary of the Board of Directors · born 1976
- Mr. Hanjing BaoDeputy General Manager · born 1984
- Ms. Li Pan LiuDeputy General Manager · born 1978
- Mr. Chun YangKey Technical Personnel · born 1981